Inhibikase Therapeutics Inc (NASDAQ:IKT) price on Thursday, July 03, rose 2.16% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $1.89.
A look at the stock’s price movement, the close in the last trading session was $1.85, moving within a range at $1.8 and $1.9. The beta value (5-Year monthly) was 0.945. Turning to its 52-week performance, $4.20 and $1.12 were the 52-week high and 52-week low respectively. Overall, IKT moved -6.90% over the past month.
Inhibikase Therapeutics Inc’s market cap currently stands at around $140.50 million, with investors looking forward to this quarter’s earnings report slated for on 2025-May-14.
Turning to the stock’s technical picture we see that short term indicators suggest on average that IKT is a 50% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
2 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 1 recommend IKT as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
IKT’s current price about 3.43% and -3.80% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 51.83, while 7-day volatility ratio is 11.44% and 7.55% in the 30-day chart. Further, Inhibikase Therapeutics Inc (IKT) has a beta value of 0.93. Analysts have given the company’s stock an average 52-week price target of $6.5, forecast between a low of $5 and high of $8. Looking at the price targets, the low is -164.55% off current price level while to achieve the yearly target high, price needs to move -323.28%. Nonetheless, investors will most likely welcome a -243.92% jump to $6.5 which is the analysts’ median price.
If we refocus on Inhibikase Therapeutics Inc (NASDAQ:IKT), historical trading data shows that trading volumes averaged 0.91 over the past 10 days and 253.24K over the past 3 months. The company’s latest data on shares outstanding shows there are 74.34 million shares.
The 38.78% of Inhibikase Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 54.55% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 1.59 million on 2025-06-13, giving us a short ratio of 13.86. The data shows that as of 2025-06-13 short interest in Inhibikase Therapeutics Inc (IKT) stood at 528.00003 of shares outstanding, with shares short rising to 1.38 million registered in 2025-05-15. Current price change has pushed the stock 52.42% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the IKT stock continues to rise going into the next quarter.
